Abstract
In the past 10 years, many widely accepted concepts relating to aldosterone production and its pathogenetic role have changed. We now know that aldosterone is produced not only by the zona glomerulosa of the adrenal cortex, but also in the heart, blood vessels, kidney and brain; such extra-epithelial production occurs mainly during tissue repair. Also, increased aldosterone levels contribute to vessel inflammation, oxidative stress, endothelial dysfunction and organ damage. As such, aldosterone has a key role in the development of myocardial fibrosis. Anti-aldosterone treatment has proven effective in patients with heart failure. Experimental evidence regarding the role of aldosterone in kidney damage has accumulated. Aldosterone infusion can counteract the beneficial effects of treatment with angiotensin-converting-enzyme inhibitors, causing more-severe proteinuria and an increased number of vascular and glomerular lesions; treatment with aldosterone antagonists can reverse these alterations. Preliminary observations in pilot studies in humans confirm the experimental findings, supporting the hypothesis that aldosterone antagonists are renoprotective in clinical practice. Studies in larger populations with longer follow-up are needed to confirm this theory.
Key Points
-
Experimental evidence supports a role for systemic and locally produced aldosterone in kidney damage that is independent of renin and angiotensin II
-
Pathophysiological effects of aldosterone include development of extracellular matrix and fibrosis, inflammation, stimulation of reactive oxygen species production, endothelial dysfunction, and cell growth and proliferation
-
Clinical studies performed to date, although being primarily small, open-label trials with short follow-up, have shown a marked antiproteinuric effect of the aldosterone antagonist spironolactone that is independent of blood pressure changes
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jafar TH et al. (2001) Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med 135: 73–87
Brenner BM et al. (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869
Lewis EJ et al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860
Simpson SA et al. (1952) Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 2: 226–228
Takeda Y et al. (1996) Regulation of aldosterone synthase in human vascular endothelial cells by angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 81: 2797–2800
Hatakeyama H et al. (1994) Vascular aldosterone: biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem 269: 24316–24320
Ahmad N et al. (2004) Do human vascular endothelial cells produce aldosterone? Endocrinology 145: 3626–3629
Silvestre JS et al. (1998) Myocardial production of aldosterone and corticosterone in the rat: physiological regulation. J Biol Chem 273: 4883–4891
Garnier A et al. (2004) Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110: 1819–1825
Ye P et al. (2005) The aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) genes are not expressed in the rat heart. Endocrinology 146: 5287–5293
Gomez-Sanchez EP et al. (2005) Is aldosterone synthesized within the rat brain? Am J Physiol Endocrinol Metab 288: E342–E346
Xue C et al. (2005) Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor. Hypertension 46: 584–590
Nishikawa T et al. (2005) Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 96: 309–316
Gomez-Sanchez EP (2004) Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Curr Opin Nephrol Hypertens 13: 191–196
Lombes M et al. (1995) Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 92: 175–182
Golestaneh N et al. (2001) Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res 280: 1300–1306
Uhrenholt TR et al. (2003) Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone. Circ Res 93: 1258–1266
Todd-Turla KM et al. (1993) Distribution of mineralocorticoid and glucocorticoid receptor mRNA along the nephron. Am J Physiol 264: F781–F791
Nishiyama A et al. (2005) Involvement of aldosterone and mineralocorticoid receptors in rat mesangial cell proliferation and deformability. Hypertension 45: 710–716
Nagai Y et al. (2005) Aldosterone stimulates collagen gene expression and synthesis via activation of ERK1/2 in rat renal fibroblasts. Hypertension 46: 1039–1045
Arima S et al. (2004) Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole. Hypertension 43: 352–357
Liu SL et al. (2003) Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation 108: 2400–2406
Brilla CG et al. (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893–901
Young MJ et al. (2003) Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 beta-hydroxysteroid dehydrogenase inactivation. Endocrinology 144: 1121–1125
Sun Y et al. (2002) Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161: 1773–1781
Pitt B et al. (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709–717
Pitt B et al. (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321
Quan ZY et al. (1992) Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int 41: 326–333
Greene EL et al. (1996) Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98: 1063–1068
Aldigier JC et al. (2005) Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 16: 3306–3314
Linz W et al. (1998) Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats. Kidney Int 54: 2037–2044
Rocha R et al. (1998) Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31: 451–458
Rocha R et al. (1999) Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33: 232–237
Rocha R et al. (2000) Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871–3878
Nagase M et al. (2006) Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47: 1084–1093
Horiuchi M et al. (1993) Characterization of renal aldosterone receptors in genetically hypertensive rats. Am J Physiol 264: F286–F291
Fujisawa G et al. (2004) Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 66: 1493–1502
Han KH et al. (2006) Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70: 111–120
Feria I et al. (2003) Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 63: 43–52
Brown NJ et al. (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58: 1219–1227
Juknevicius I et al. (2004) Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol Renal Physiol 286: F1059–F1062
Nishiyama A et al. (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension 43: 841–848
Miyata K et al. (2005) Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16: 2906–2912
Blasi ER et al. (2003) Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63: 1791–1800
Ma J et al. (2006) Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int 69: 1064–1072
Conn JW (1955) Presidential address. Part II: Primary hyperaldosteronism: a new clinical syndrome. J Lab Clin Med 45: 3–17
Conn JW et al. (1964) Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 107: 159–172
Ribstein J et al. (2005) Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 16: 1320–1325
Sechi LA et al. (2006) Long-term renal outcomes in patients with primary aldosteronism. JAMA 295: 2638–2645
Chrysostomou A et al. (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345: 925–926
Sato A et al. (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64–68
Sato A et al. (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18: 44–49
Bianchi S et al. (2005) Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 46: 45–51
Schjoedt KJ et al. (2005) Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68: 2829–2836
Schjoedt KJ et al. (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70: 536–542
Rachmani R et al. (2004) The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 21: 471–475
Takebayashi K et al. (2006) Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91: 2214–2217
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Vecchio, L., Procaccio, M., Viganò, S. et al. Mechanisms of Disease: the role of aldosterone in kidney damage and clinical benefits of its blockade. Nat Rev Nephrol 3, 42–49 (2007). https://doi.org/10.1038/ncpneph0362
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncpneph0362
This article is cited by
-
Increased risk of metastasis in patients with incidental use of renin-angiotensin system inhibitors: a retrospective analysis for multiple types of cancer based on electronic medical records
Hypertension Research (2022)
-
Relation of multi-marker panel to incident chronic kidney disease and rapid kidney function decline in African Americans: the Jackson Heart Study
BMC Nephrology (2018)
-
Aldosterone and glomerular filtration – observations in the general population
BMC Nephrology (2014)
-
Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children
Pediatric Nephrology (2009)
-
Aldosterone and diabetic kidney disease
Current Diabetes Reports (2009)